Technical Analysis for ATNM - Actinium Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
F 1.39 -2.11% -0.03
ATNM closed down 2.11 percent on Wednesday, November 20, 2024, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
NR7 Range Contraction 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Wide Bands Range Expansion 0.00%
Below Lower BB Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
Jack-in-the-Box Bearish Bearish Swing Setup -2.11%
Lower Bollinger Band Walk Weakness -2.11%
Wide Bands Range Expansion -2.11%

   Recent Intraday Alerts

Alert Time
Rose Above Lower Bollinger Band about 20 hours ago
1.5x Volume Pace about 20 hours ago
Jack-in-the-Box Bearish Entry about 20 hours ago
Fell Below Previous Day's Low about 20 hours ago
Down 2 % about 20 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Actinium Pharmaceuticals, Inc. Description

Actinium Pharmaceuticals, Inc., formerly Cactus Ventures, Inc. is a biopharmaceutical company developing cancer drugs. The Company's advanced products are Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), in human clinical trials for acute myeloid leukemia (AML) and Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used in myeloconditioning for hematopoietic stem cells transplantation (HSCT) in various indications. In addition, the Ac-225 based drugs development relies on the patented Alpha Particle Immunotherapy Technology (APIT) platform technology co-developed with Memorial Sloan- Kettering Cancer Center (MSKCC), a related institution. The APIT technology couples monoclonal antibodies (mAb) with extremely potent but comparatively safe alpha particle emitting radioactive isotopes, in particular actinium 225 and bismuth 213.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Immunology Natural Sciences Immunotherapy Antibodies Chemical Elements Monoclonal Antibodies Monoclonal Antibody Stem Cell Acute Myeloid Leukemia Transplantation Platform Technology Actinides Cancer Center Hematopoietic Stem Cell Iodine Bismuth Immunotherapy Technology Kettering Cancer Center Memorial Sloan

Is ATNM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 10.24
52 Week Low 1.33
Average Volume 274,818
200-Day Moving Average 5.48
50-Day Moving Average 1.76
20-Day Moving Average 1.73
10-Day Moving Average 1.66
Average True Range 0.13
RSI (14) 32.43
ADX 21.29
+DI 12.89
-DI 30.47
Chandelier Exit (Long, 3 ATRs) 1.59
Chandelier Exit (Short, 3 ATRs) 1.76
Upper Bollinger Bands 2.06
Lower Bollinger Band 1.39
Percent B (%b) 0.0
BandWidth 39.04
MACD Line -0.10
MACD Signal Line -0.06
MACD Histogram -0.0441
Fundamentals Value
Market Cap 38.59 Million
Num Shares 27.8 Million
EPS -1.93
Price-to-Earnings (P/E) Ratio -0.72
Price-to-Sales 266.69
Price-to-Book 3.48
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.51
Resistance 3 (R3) 1.52 1.49 1.49
Resistance 2 (R2) 1.49 1.46 1.49 1.48
Resistance 1 (R1) 1.44 1.44 1.43 1.43 1.48
Pivot Point 1.41 1.41 1.40 1.41 1.41
Support 1 (S1) 1.36 1.38 1.35 1.35 1.30
Support 2 (S2) 1.33 1.36 1.33 1.30
Support 3 (S3) 1.28 1.33 1.29
Support 4 (S4) 1.27